Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=52 Dose Escalation and Remission (DEAR)
Ulcerative Colitis
Primary: Fecal Calprotectin Level <50µg/g — 7; 1 participants
N/A N=396 Follow-up Protocol on the Outcome of Frozen-thawed Embryo Transfer Cycles From Clinical Trial P05690 (P05711)
In Vitro Fertilization
Primary: Percentage of Participants With an Ongoing Pregnancy (Cumulative Ongoing Pregnancy Rate) — 32.1; 41.4 Percentage of participants
Phase 3 N=62 Cognitive Remediation With D-Cycloserine
Smoking Cessation
Primary: Effect of D-cycloserine + Cue-exposure Treatment on Continuous Abstinence From Tobacco Smoking. — 9; 30 percentage of participants
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Phase 4 N=55 The Jetstream G3™ Calcium Study
Peripheral Arterial Disease
Primary: Luminal Area Change — 5.1; 8.3 mm^2 — p=<0.0001
Phase 4 N=647 Multicenter Infection Surveillance Study Following Open Heart Surgery
Surgery · Pneumonia · Surgical Site Infection
Primary: Hospital Acquired Pneumonia — 8; 18 participants
N/A N=58 Comparison of 18F FDG PET/CT TO PET MRI
Any Condition With a Clinical Indication for PET/CT Exam
Primary: PET/MR Images Clinical Usefulness — 51 Participants
Phase 3 N=25 Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B
Hemophilia B
Primary: Annualized Number of Bleeding Episodes. — 32.9; 3.6 Number of bleeds per year — p=<0.0001
N/A N=442 Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
Heparin Induced Thrombocytopenia
Primary: Time to Occurrence of a Composite Triple Endpoint Consisting of Death, Limb Amputation/Gangrene, and New Thrombosis — 17.5; 27.8; 31.4 days — p=0.003
Phase 2 N=12 PET Imaging With Tc-94m Sestamibi to Assess Resistance to Chemotherapy
Cancer
Primary: Percent Change in Tc-94m Sestamibi Body Weight Standardized Uptake Value (SUV) Maximum in Tumor Tissue Before and After Administration of Tariquidar, a P-glycoprotein…
N/A N=450 Temple Registry for the Investigation of African American Gastrointestinal Disease Epidemiology
Gastroesophageal Reflux Disease · Functional Bowel Disorders
Primary: Epidemiologic Factors Associated With Prevalent Reflux Disease. — 17.6 percentage of participants with GERD
Phase 3 N=378 A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
Rheumatoid Arthritis
Primary: Percentage of Participants With a Response as Determined by American College of Rheumatology (ACR) 20% Improvement (ACR20) — 64.2; 63.9; 72.0 percentage of participants…
N/A N=21 Inflammatory Cytokine Quantification in Infants
Sepsis · Congenital Diaphragmatic Hernia · Neonatal Cardiopulmonary Failure
Primary: TNF-alpha, Baseline — 8.88 pg/mL
N/A N=1,389 PASCOE-Agil HOM-Injektopas in the Treatment of Rheumatic Disorders
Rheumatic Diseases · Arthralgia · Myalgias/Myopathy
Primary: Visual Analog Scale (VAS) — 6.57; 4.23; 2.61 units on a scale